Mineralys Therapeutics Inc expected to post a loss of 67 cents a share - Earnings Preview

Mineralys Therapeutics

07/05/2024 14:57

* Mineralys Therapeutics Inc  MLYS.OQ   MLYS.O  is expected
to show no change in quarterly revenue when it reports 
results on May 9 for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Mineralys Therapeutics
Inc is
for a loss of 67 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Mineralys
Therapeutics Inc is $32.50​, above​ its last closing price
of $13.75. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023              -0.82      -0.61     Beat    26.1
 Sep. 30 2023  -0.70       -0.76      -0.57     Beat    25
 Jun. 30 2023  -0.67       -0.72      -0.31     Beat    56.9​
 Jan. 1 0001   -0.88       -0.89      -0.51     Beat    42.7
 ​​Dec.        -1.72       -1.72      -1.74     Missed  -1.2
 31 2022                                                
                                                        ​
 This summary was machine generated May 7 at 13:57 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)